{"id":33341,"date":"2006-05-09T00:00:00","date_gmt":"2006-05-09T03:00:00","guid":{"rendered":"https:\/\/clam.fw2web.com.br\/es\/2006\/05\/09\/convocatoria-abierta-para-asistir-a-la-reunion-mundial-sobre-arvs-de-abbot-y-gilead-en-londres\/"},"modified":"2006-05-09T00:00:00","modified_gmt":"2006-05-09T03:00:00","slug":"convocatoria-abierta-para-asistir-a-la-reunion-mundial-sobre-arvs-de-abbot-y-gilead-en-londres","status":"publish","type":"post","link":"https:\/\/clam.org.br\/es\/agenda\/convocatoria-abierta-para-asistir-a-la-reunion-mundial-sobre-arvs-de-abbot-y-gilead-en-londres\/33341\/","title":{"rendered":"Convocatoria abierta para asistir a la Reuni\u00f3n Mundial sobre ARVs de ABBOT y GILEAD en Londres"},"content":{"rendered":"<p><P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\">Del 12 al 14 de Julio del 2006 la International Treatment Preparedness Coalition&nbsp; (ITPC en ingl\u00e9s y en Latinoam\u00e9rica CIAT -Coalici\u00f3n Internacional de Activistas en Tratamientos-) patrocinar\u00e1 la tercera reuni\u00f3n del Consejo Consultivo de la Comunidad Mundial (WorldCAB) sobre reg\u00edmenes de tratamiento anti-retroviral de segunda l\u00ednea con Laboratorios Abbot y Gilead Sciences, productores de una nueva f\u00f3rmula estable al calor y de ritonavir\/lopinavir y tenofovir, respectivamente. <\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><?xml:namespace prefix = o ns = \"urn:schemas-microsoft-com:office:office\" \/><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\">&nbsp;<\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoBodyText style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\">Si usted desea asistir a esa reuni\u00f3n en representaci\u00f3n de Latinoam\u00e9rica, debe responder las siguientes preguntas y enviar las respuestas a <SPAN style=\"COLOR: blue\"><a href=\"http:\/\/us.f603.mail.yahoo.com\/ym\/Compose?To=coordinacion.ciat@gmail.com\" target=\"_blank\" rel=\"noopener\"><SPAN style=\"COLOR: blue\">coordinacion.ciat@gmail.com<\/SPAN><\/A><\/SPAN> antes del 18 de mayo de 2006.<\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoBodyText style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\">&nbsp;<\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\">1. \u00bfCu\u00e1l es su inter\u00e9s espec\u00edfico en temas relacionados con la disponibilidad y acceso a ARVs de segunda l\u00ednea, en particular de tenofovir y la nueva f\u00f3rmula de ritonavir\/lopinavir? <\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\"><SPAN style=\"mso-spacerun: yes\">&nbsp;<\/SPAN><BR> 2. \u00bfQu\u00e9 trabajo espec\u00edfico ha realizado usted a nivel local acerca del registro de medicamentos y cuestiones de precio? <\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\"><BR> 3. \u00bfQu\u00e9 tipo de conocimiento o experiencia tiene en lo que se refiere a leyes nacionales e internacionales relacionadas con la regulaci\u00f3n de medicamentos? <\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\"><BR> 4. \u00bfCu\u00e1les son sus actividades para promover el acceso a medicamentos en su pa\u00eds? <\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\"><SPAN style=\"mso-spacerun: yes\">&nbsp;<\/SPAN><BR> 5. \u00bfC\u00f3mo usar\u00e1 su experiencia para promover posteriormente el acceso a tratamiento de segunda l\u00ednea en su pa\u00eds? <\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\"><SPAN style=\"mso-spacerun: yes\">&nbsp;<\/SPAN><BR> 6. \u00bfCu\u00e1l es su inter\u00e9s acerca de desarrollo de medicamentos, investigaci\u00f3n cl\u00ednica y operativo sobre tratamiento para SIDA; inter\u00e9s en literatura de investigaci\u00f3n, ensayos cl\u00ednicos en general; experiencia con cuestiones de cabildeo e incidencia pol\u00edtica o trabajo program\u00e1tico en estas \u00e1reas; por ejemplo, a trav\u00e9s de su participaci\u00f3n en el la CAB en su pa\u00eds? <\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\"><BR> 7. Que problemas han tenido en su pa\u00eds relacionados con los medicamentos que producen los laboratorios Abbot y Gilead Sciences? <\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\">&nbsp;<\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\">8. Que precios tienen los medicamentos producidos por los mencionados laboratorios en su pa\u00eds (precios en d\u00f3lares) <\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\">&nbsp;<\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\">8. \u00bfEn que forma usted se compromete a replicar la informaci\u00f3n de lo ocurrido en la reuni\u00f3n de Londres? <\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\">&nbsp;<\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\">9. \u00bfEn cuanto tiempo usted tendr\u00e1 disponible el informe luego de terminada la reuni\u00f3n? <\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\">&nbsp;<\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\">10. \u00bfEn que pa\u00eds y ciudad se encuentra usted? cuales son sus datos de contacto? (correo electr\u00f3nico, tel\u00e9fonos y direcci\u00f3n) <\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\">&nbsp;<\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\">CONVOCA EL CONSEJO REGIONAL DE LA COALICI\u00d3N INTERNACIONAL DE ACTIVISTAS EN TRATAMIENTO DE LATINOAM\u00c9RICA &ndash; CIAT <\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\">&nbsp;<\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\">Berta Chete<\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\">Jaime Argueta<\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\">Jos\u00e9 M\u00e9ndez<\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\">Oswaldo Rada<\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\">Patricia P\u00e9rez<\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\">Stella Carrizo<\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P> <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 14.4pt; TEXT-ALIGN: justify\"><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO; mso-bidi-font-weight: bold\">Germ\u00e1n Humberto Rinc\u00f3n Perfetti<\/SPAN><SPAN lang=ES-CO style=\"FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-ansi-language: ES-CO\"><o_p><\/o_p><\/SPAN><\/P><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Del 12 al 14 de Julio del 2006 la International Treatment Preparedness Coalition (ITPC en ingl\u00e9s y en Latinoam\u00e9rica CIAT -Coalici\u00f3n Internacional de Activistas en Tratamientos-) patrocinar\u00e1 la tercera reuni\u00f3n del Consejo Consultivo de la Comunidad Mundial (WorldCAB) sobre reg\u00edmenes de tratamiento anti-retroviral de segunda l\u00ednea con Laboratorios Abbot y Gilead Sciences, productores de una nueva f\u00f3rmula estable al calor y de ritonavir\/lopinavir y tenofovir, respectivamente.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"default","ast-global-header-display":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[],"class_list":["post-33341","post","type-post","status-publish","format-standard","hentry","category-agenda"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Convocatoria abierta para asistir a la Reuni\u00f3n Mundial sobre ARVs de ABBOT y GILEAD en Londres - CLAM - ES<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/clam.org.br\/es\/agenda\/convocatoria-abierta-para-asistir-a-la-reunion-mundial-sobre-arvs-de-abbot-y-gilead-en-londres\/33341\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Convocatoria abierta para asistir a la Reuni\u00f3n Mundial sobre ARVs de ABBOT y GILEAD en Londres - CLAM - ES\" \/>\n<meta property=\"og:description\" content=\"Del 12 al 14 de Julio del 2006 la International Treatment Preparedness Coalition (ITPC en ingl\u00e9s y en Latinoam\u00e9rica CIAT -Coalici\u00f3n Internacional de Activistas en Tratamientos-) patrocinar\u00e1 la tercera reuni\u00f3n del Consejo Consultivo de la Comunidad Mundial (WorldCAB) sobre reg\u00edmenes de tratamiento anti-retroviral de segunda l\u00ednea con Laboratorios Abbot y Gilead Sciences, productores de una nueva f\u00f3rmula estable al calor y de ritonavir\/lopinavir y tenofovir, respectivamente.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/clam.org.br\/es\/agenda\/convocatoria-abierta-para-asistir-a-la-reunion-mundial-sobre-arvs-de-abbot-y-gilead-en-londres\/33341\/\" \/>\n<meta property=\"og:site_name\" content=\"CLAM - ES\" \/>\n<meta property=\"article:published_time\" content=\"2006-05-09T03:00:00+00:00\" \/>\n<meta name=\"author\" content=\"fw2\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"fw2\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/clam.org.br\/es\/agenda\/convocatoria-abierta-para-asistir-a-la-reunion-mundial-sobre-arvs-de-abbot-y-gilead-en-londres\/33341\/\",\"url\":\"https:\/\/clam.org.br\/es\/agenda\/convocatoria-abierta-para-asistir-a-la-reunion-mundial-sobre-arvs-de-abbot-y-gilead-en-londres\/33341\/\",\"name\":\"Convocatoria abierta para asistir a la Reuni\u00f3n Mundial sobre ARVs de ABBOT y GILEAD en Londres - CLAM - ES\",\"isPartOf\":{\"@id\":\"https:\/\/clam.org.br\/es\/#website\"},\"datePublished\":\"2006-05-09T03:00:00+00:00\",\"author\":{\"@id\":\"https:\/\/clam.org.br\/es\/#\/schema\/person\/fbd9a86032bf7479f94b0ded196f1010\"},\"breadcrumb\":{\"@id\":\"https:\/\/clam.org.br\/es\/agenda\/convocatoria-abierta-para-asistir-a-la-reunion-mundial-sobre-arvs-de-abbot-y-gilead-en-londres\/33341\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/clam.org.br\/es\/agenda\/convocatoria-abierta-para-asistir-a-la-reunion-mundial-sobre-arvs-de-abbot-y-gilead-en-londres\/33341\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/clam.org.br\/es\/agenda\/convocatoria-abierta-para-asistir-a-la-reunion-mundial-sobre-arvs-de-abbot-y-gilead-en-londres\/33341\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/clam.org.br\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Convocatoria abierta para asistir a la Reuni\u00f3n Mundial sobre ARVs de ABBOT y GILEAD en Londres\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/clam.org.br\/es\/#website\",\"url\":\"https:\/\/clam.org.br\/es\/\",\"name\":\"CLAM - ES\",\"description\":\"S\u00f3 mais um site CLAM - Centro Latino-Americano em Sexualidade e Direitos Humanos sites\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/clam.org.br\/es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/clam.org.br\/es\/#\/schema\/person\/fbd9a86032bf7479f94b0ded196f1010\",\"name\":\"fw2\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/clam.org.br\/es\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c38472c0cdbde82d9b6fcc26adb3779d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c38472c0cdbde82d9b6fcc26adb3779d?s=96&d=mm&r=g\",\"caption\":\"fw2\"},\"sameAs\":[\"https:\/\/clam.fw2web.com.br\"],\"url\":\"https:\/\/clam.org.br\/es\/author\/fw2\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Convocatoria abierta para asistir a la Reuni\u00f3n Mundial sobre ARVs de ABBOT y GILEAD en Londres - CLAM - ES","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/clam.org.br\/es\/agenda\/convocatoria-abierta-para-asistir-a-la-reunion-mundial-sobre-arvs-de-abbot-y-gilead-en-londres\/33341\/","og_locale":"es_ES","og_type":"article","og_title":"Convocatoria abierta para asistir a la Reuni\u00f3n Mundial sobre ARVs de ABBOT y GILEAD en Londres - CLAM - ES","og_description":"Del 12 al 14 de Julio del 2006 la International Treatment Preparedness Coalition (ITPC en ingl\u00e9s y en Latinoam\u00e9rica CIAT -Coalici\u00f3n Internacional de Activistas en Tratamientos-) patrocinar\u00e1 la tercera reuni\u00f3n del Consejo Consultivo de la Comunidad Mundial (WorldCAB) sobre reg\u00edmenes de tratamiento anti-retroviral de segunda l\u00ednea con Laboratorios Abbot y Gilead Sciences, productores de una nueva f\u00f3rmula estable al calor y de ritonavir\/lopinavir y tenofovir, respectivamente.","og_url":"https:\/\/clam.org.br\/es\/agenda\/convocatoria-abierta-para-asistir-a-la-reunion-mundial-sobre-arvs-de-abbot-y-gilead-en-londres\/33341\/","og_site_name":"CLAM - ES","article_published_time":"2006-05-09T03:00:00+00:00","author":"fw2","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"fw2","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/clam.org.br\/es\/agenda\/convocatoria-abierta-para-asistir-a-la-reunion-mundial-sobre-arvs-de-abbot-y-gilead-en-londres\/33341\/","url":"https:\/\/clam.org.br\/es\/agenda\/convocatoria-abierta-para-asistir-a-la-reunion-mundial-sobre-arvs-de-abbot-y-gilead-en-londres\/33341\/","name":"Convocatoria abierta para asistir a la Reuni\u00f3n Mundial sobre ARVs de ABBOT y GILEAD en Londres - CLAM - ES","isPartOf":{"@id":"https:\/\/clam.org.br\/es\/#website"},"datePublished":"2006-05-09T03:00:00+00:00","author":{"@id":"https:\/\/clam.org.br\/es\/#\/schema\/person\/fbd9a86032bf7479f94b0ded196f1010"},"breadcrumb":{"@id":"https:\/\/clam.org.br\/es\/agenda\/convocatoria-abierta-para-asistir-a-la-reunion-mundial-sobre-arvs-de-abbot-y-gilead-en-londres\/33341\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/clam.org.br\/es\/agenda\/convocatoria-abierta-para-asistir-a-la-reunion-mundial-sobre-arvs-de-abbot-y-gilead-en-londres\/33341\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/clam.org.br\/es\/agenda\/convocatoria-abierta-para-asistir-a-la-reunion-mundial-sobre-arvs-de-abbot-y-gilead-en-londres\/33341\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/clam.org.br\/es\/"},{"@type":"ListItem","position":2,"name":"Convocatoria abierta para asistir a la Reuni\u00f3n Mundial sobre ARVs de ABBOT y GILEAD en Londres"}]},{"@type":"WebSite","@id":"https:\/\/clam.org.br\/es\/#website","url":"https:\/\/clam.org.br\/es\/","name":"CLAM - ES","description":"S\u00f3 mais um site CLAM - Centro Latino-Americano em Sexualidade e Direitos Humanos sites","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/clam.org.br\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/clam.org.br\/es\/#\/schema\/person\/fbd9a86032bf7479f94b0ded196f1010","name":"fw2","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/clam.org.br\/es\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c38472c0cdbde82d9b6fcc26adb3779d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c38472c0cdbde82d9b6fcc26adb3779d?s=96&d=mm&r=g","caption":"fw2"},"sameAs":["https:\/\/clam.fw2web.com.br"],"url":"https:\/\/clam.org.br\/es\/author\/fw2\/"}]}},"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clam.org.br\/es\/wp-json\/wp\/v2\/posts\/33341","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clam.org.br\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clam.org.br\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clam.org.br\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clam.org.br\/es\/wp-json\/wp\/v2\/comments?post=33341"}],"version-history":[{"count":0,"href":"https:\/\/clam.org.br\/es\/wp-json\/wp\/v2\/posts\/33341\/revisions"}],"wp:attachment":[{"href":"https:\/\/clam.org.br\/es\/wp-json\/wp\/v2\/media?parent=33341"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clam.org.br\/es\/wp-json\/wp\/v2\/categories?post=33341"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clam.org.br\/es\/wp-json\/wp\/v2\/tags?post=33341"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}